Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

Castration-resistant prostate cancer (CRPC) is now the second most common cause of male cancer-related mortality. Although docetaxel has recently been shown to extend the survival of patients with CRPC in two large randomised phase III studies, subsequent treatment options remain limited for these p...

Descripción completa

Detalles Bibliográficos
Autores principales: Attard, G, Sarker, D, Reid, A, Molife, R, Parker, C, de Bono, J S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360544/
https://www.ncbi.nlm.nih.gov/pubmed/16983403
http://dx.doi.org/10.1038/sj.bjc.6603223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360544/
https://www.ncbi.nlm.nih.gov/pubmed/16983403
http://dx.doi.org/10.1038/sj.bjc.6603223

Ejemplares similares